ABBV - AbbVie

-

$undefined

N/A

(N/A)

AbbVie NEW YORK STOCK EXCHANGE INC.:ABBV AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Location: 1 N Waukegan Rd, Illinois, 60064-1802, US | Website: www.abbvie.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

408.6B

Cash

5.555B

Avg Qtr Burn

N/A

Short % of Float

0.96%

Insider Ownership

0.10%

Institutional Own.

73.98%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RINVOQ (upadacitinib) Details
Giant Cell Arteritis (GCA)

Approved

Quarterly sales

TrenibotulinumtoxinE (TrenibotE) Details
Moderate to Severe Glabellar Lines

BLA

Acceptance for review

Tavapadon Details
Parkinson's disease, Brain disease

Phase 3

Update

Tavapadon (adjunct with L-Dopa) Details
Parkinson's disease, Brain disease

Phase 3

Update

Darigabat Details
Social Anxiety Disorder, Panic Disorder

Phase 2

Update

Phase 2

Update

Emraclidine (CVL-231) Details
Brain disease, Schizophrenia

Phase 2

Update

Phase 2

Update

NX-13 Details
Ulcerative colitis

Phase 2

Update

CVL-354 Details
Major depressive disorder

Phase 1

Update

Emraclidine (CVL-231) Details
Brain disease, Neurodegenerative disease, Alzheimer's disease

Phase 1

Update